SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is surging on news of a massive, multi-year AI cloud services agreement with Microsoft, driving significant community excitement. Investors are drawing parallels to similar deals in the sector, anticipating a substantial upside, while also highlighting the company's strategic positioning in the AI infrastructure space. The conversation also involves speculation around potential earnings catalysts and further expansion opportunities.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as the community anticipates upcoming earnings, with some analysts predicting the stock could double its market cap. Bullish sentiment abounds, with some traders drawing comparisons to other high-growth tech stocks. However, concerns about high valuation and potential for a post-earnings pullback remain discussion points.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp sell-off possibly linked to news of a lawsuit against a former FDA official, which is creating uncertainty around the stock. The community is discussing the implications of this news, potential manipulation, and the company's upcoming earnings report. Some investors speculate about a buyout or partnership, while others express concern about the company's leadership and its impact on the stock's performance.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as traders discuss whether it's setting up for a similar breakout to Amazon, focusing on accumulation patterns and potential FOMO. Some investors are frustrated with the stock's recent performance despite positive earnings, while others see it as an undervalued long-term play, especially with upcoming events like the World Cup and Olympics.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is gaining attention as traders discuss its potential for a significant price movement, drawing comparisons to other low-float stocks that have experienced substantial short squeezes. Community members are actively watching the stock, citing its low float and speculating about news catalysts. Some believe a coordinated effort from retail investors could lead to a squeeze comparable to previous high-profile situations.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a volatile reaction to recent FDA feedback regarding its Huntington's disease treatment, AMT-130; while the company believes the FDA is aligned for accelerated approval, the agency has voiced concerns around data adequacy. The community is actively debating the FDA's shifting stance, potential delays, and the overall implications for the company's future, with some suggesting a possible buyout while some expect that $QURE is overvalued.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending following positive clinical data from its TERN-701 trial, selected for oral presentation at an upcoming hematology conference, driving speculation of a potential buyout. Community members are weighing the bullish data against a recent $300M shelf registration, debating short-squeeze potential versus dilution risks. The focus shifts to TERN's oncology program after the discontinuation of their GLP-1 candidate, with some viewing it as a streamlined path to acquisition.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

LCID is trending amid concerns about its financial health and the overall EV market, despite partnerships with Nvidia and Uber. The community is discussing potential dilution, comparing it unfavorably to Tesla, and questioning its long-term viability. Bearish sentiment seems to be dominating, with some anticipating further declines and new all-time lows.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

LLY is trending as investors digest recent news, including strong phase 3 data for its oral GLP-1 orforglipron and potential impacts from government negotiations on drug pricing. Community discussions revolve around the drug's potential, target prices, and the ongoing competition within the weight loss and diabetes markets. Some are also discussing potential deals in the sector.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as the community discusses its potential for growth, particularly regarding its QNX technology and partnerships with major tech companies. Some investors believe the current stock price undervalues the company's assets and future prospects, while others point to potential market manipulation and short-selling tactics affecting the stock's performance. The potential impact of government support and expansion in Asian markets are also being closely watched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Australia’s Web Travel hits over 7-mth high on strong FY earnings, outlook

Investing.com-- Shares of Web Travel Group (ASX:WEB) surged to a seven-month high on Wednesday after the company said its annual net profit almost tripled, boosted by the successful demerger of its B2C businesses and strong performance from its core WebBeds B2B travel division.

Web.com Group, Inc. engages in the provision of Internet services and online marketing solutions for small to medium-sized businesses. The firm's solutions include domains, hosting, website design and management, search engine optimization, online marketing campaigns, local sales leads, social media, mobile products, and eCommerce solutions. The company was founded in 1997 and is headquartered in Jacksonville, FL.

Web.com Group, Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

WEB
Web.com Group, Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest WEB News

WEBWeb.com Group, Inc.